Q-omics provides the consensus-scored RPS27AP15 profile across patient tissues and cancer cell-line models. RPS27AP15 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RPS27AP15 is differentially expressed in 4, with the highest sampling consensus in PAAD. Additionally, RPS27AP15 RNA expression shows 5,312 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRP, PAAD, and STAD as cancer lineages where RPS27AP15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS27AP15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS27AP15 survival associations across molecular data types. RPS27AP15 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS27AP15 RNA expression–survival associations across cancer types. High RPS27AP15 expression shows unfavorable associations in KIRP, TGCT, CESC, LUSC and PRAD, but favorable associations in HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify KIRP as the clearest survival context for RPS27AP15 RNA expression.
This table summarizes RPS27AP15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS27AP15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS27AP15 shows lower tumor expression in PAAD, KIRC, BRCA and THCA. The PAAD box plot shows higher RPS27AP15 RNA expression in normal versus tumor tissue (log2 FC = −0.157, t-test p = .030).
This table shows molecular features associated with RPS27AP15 in patient tissues and cancer cell lines. In patient samples, RPS27AP15 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
